Compare · IVVD vs PFE
IVVD vs PFE
Side-by-side comparison of Invivyd Inc. (IVVD) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IVVD focuses on Biotechnology: Biological Products (No Diagnostic Substances), while PFE focuses on Biotechnology: Pharmaceutical Preparations.
- PFE is the larger of the two at $167.83B, about 941.7x IVVD ($178.2M).
- PFE has been more active in the news (14 items in the past 4 weeks vs 2 for IVVD).
- PFE has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- Invivyd Inc.
- Pfizer Inc.
- Price
- -
- -
- Market cap
- $178.2M
- $167.83B
- 1M return
- -
- +3.77%
- 1Y return
- -
- +13.79%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 14
- Recent ratings
- 7
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest IVVD
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
- Invivyd to Participate in Upcoming September Investor Conferences
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sheffield Ian
- SEC Form 3 filed by new insider Sheffield Ian
Latest PFE
- Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- FDA Approval for HYMPAVZI issued to PFIZER INC
- Pfizer downgraded by DZ Bank
- Pfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Election Day Trading Splits the Benchmarks, With the Dow Lower and the Nasdaq Higher
- Chairman & CEO Bourla Albert was granted 20 units of Phantom Stock Units SSP (SEC Form 4)
- SEC Form 10-Q filed by Pfizer Inc.
- Pfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance